Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for guadecitabine plus nivolumab is displayed, with details on the study plan, participant criteria, outcomes, locations, and record history. The previous error page is no longer shown.SummaryDifference50%

- Check13 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page continues to show a 403 Forbidden error instead of the clinical study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH announcement about using “Super Intelligence” instead of “Artificial Intelligence” appears above the existing 403 error page. The footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page for NCT03576963 now renders a 403 Forbidden response. It replaces the study content with a 403 message and a minimal header, blocking access to the study details.SummaryDifference19%

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.